Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluciclovine PET/MR for Glioma Pseudoprogression
NCT04114370Phase 1Completed
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in glioma. Primary endpoint: Ability of [F-18]fluciclovine to differentiate radionecrosis (pseudoprogression) from tumor recurrence (progression) at 90 minutes. Started Oct 2019; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04114370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114370.